IP.com to Sponsor Webinar on Deciding What Is Worth Patenting in the AI Era

IP.com will sponsor a free Sept. 3, 2026 webinar hosted by IPWatchdog focused on AI-assisted patent drafting and the early “decision gates” for what is worth patenting. The session argues AI can generate polished applications quickly, but cannot replace human judgment on novelty/nonobviousness and commercial relevance. Speakers from IBM, Brandeis University, Canon, and Kodak Alaris will discuss evidence-based, traceable patentability assessments.

Analysis

This is mostly a positioning signal, not a revenue event: the market takeaway is that AI is moving patenting spend upstream from drafting labor to invention screening, prior-art search, and defensible documentation. That re-ranks winners toward vendors with corpus depth, workflow integration, and auditability; generic drafting automation is the part most likely to be commoditized first.

IBM gets the cleanest, though still modest, read-through because the message aligns with its enterprise AI pitch: regulated buyers want decision support, not just text generation. The financial impact is likely buried inside broader software bookings, so any effect should show up over 1-3 quarters through pipeline commentary rather than immediate EPS. Canon and Kodak Alaris are more relationship/brand beneficiaries than direct monetary winners.

The contrarian view is that AI may reduce low-quality patent filings rather than expand total volume. If that happens, law firms and workflow vendors exposed to drafting throughput lose, while legal analytics/search names gain pricing power from higher-value triage. The thesis breaks if management starts quantifying material attach rates or if filing volumes rise instead of flattening over the next 6-12 months.

Key Decisions for Investors

• No trade in AERA, CAJPY, or IPST on this item; treat it as a low-signal industry thought-leadership event with no immediate P&L relevance.
• Keep IBM on the watchlist into the next earnings cycle; use a 3%-5% pullback to add only if management reiterates watsonx traction in compliance/workflow use cases. Falsifier: no uplift in software bookings or AI-related pipeline commentary over the next 1-2 quarters.
• Long TRI on weakness as a beneficiary of evidence-based legal research and workflow auditability; 3-6 month horizon, with upside if enterprise buyers shift budget from drafting automation to search/validation. Exit if recurring revenue growth fails to reaccelerate.
• Avoid chasing any broad 'AI patenting' basket here; the likely winner is workflow intelligence, not document generation. If patent filing volumes inflect lower over 6-12 months, rotate away from service-heavy legal-tech exposure.